Cofactor Genomics Cements Clinical Diagnostic Plans as Immunotherapy Prediction Data Builds
NEW YORK – Cofactor Genomics has expanded the exploration of potential clinical applications for its immune modeling technology, with new proof-of-concept data published this month from a study that used the firm’s predictive immune modeling technology, ImmunoPrism, to analyze a small cohort of high-grade serous ovarian cancer tumors.
Get the full story with
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.